Nightingale App is a clinical decision support solution designed to provide evidence-based interventions for individuals with autism and related disorders. With a commitment to equipping service providers with the tools for administering high-quality, personalized treatment, Nightingale addresses the pressing need for effective care in the face of alarming statistics. According to the CDC, 1 in 68 children in the U.S. are diagnosed with autism, contributing to an estimated 1.5 million Americans living with the condition. While there is no known cure or scientifically proven pharmaceutical treatment for autism, its symptoms can be managed through evidence-based interventions such as applied behavior analysis, speech-language pathology, and occupational therapy.
Nightingale offers a suite of HIPAA-compliant data collection, reporting, and analytics tools that can be tailored to any curriculum and utilized in any setting. By simplifying data management and analytics, the platform allows service providers to allocate more time to creating high-quality curriculums and working directly with clients. Since its founding in 2013, the startup has garnered significant attention in the Health Care and Information Technology industries. Notably, Nightingale secured an impressive $660.00KSeed Round investment on 24 March 2015, with contributions from prominent investors including Y Combinator, StartX, Maverick Global Ventures, Keith Rabois, and Jaan Tallinn.
